Abstract
Background: Neuropathological studies indicate concomitant Alzheimer’s disease (AD) pathology in patients with dementia with Lewy bodies (DLB). Objectives: To measure cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ<sub>42</sub>), total tau protein (τ<sub>T</sub>), and tau phosphorylated at threonine 181 (τ<sub>P-181</sub>) in 38 patients fulfilling the diagnostic criteria of probable DLB according to the most recent (4th consensus) report. Methods: Double-sandwich commercial ELISAs (Innotest; Fujirebio, Gent, Belgium) were used for measurements. Results: According to the current cutoff values of our laboratory, 4 biomarker profiles were noted: abnormal levels of Aβ<sub>42</sub> only (44.7%), full AD profile (39.5%), abnormal levels of τ<sub>T</sub> only (5.3%), and normal levels of all 3 biomarkers (10.5%). AD profile was associated with female sex, older age, lower education, and lower MMSE scores. Conclusions: Reduction in Αβ<sub>42</sub> in DLB may be more common (>80% of patients) than previously thought, and ∼40% may have the typical CSF AD biomarker profile. AD biochemistry in DLB may be an evolving process showing increasing frequency with disease progression.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
